Oral acyclovir therapy of recurrent herpes simplex virus type 2 infection of the hand.

AUTOR(ES)

Gill, M J

RESUMO

Acyclovir was evaluated as treatment of recurrent herpes simplex virus type 2 infection of the hand in a double-blind, placebo-controlled crossover study. In nine fully evaluable patients, oral acyclovir (2 g/day in three doses for 10 days) initiated during the earliest phase of a recurrence reduced the mean durations (+/- standard deviation) of clinical symptoms from 10.1 (+/- 3.6) to 3.7 (+/- 3.0) days (P = 0.008), signs from 11.1 (+/- 3.7) to 6.2 (+/- 3.3) days (P = 0.024), and viral positivity from 5.3 (+/- 3.8) to 0.6 (+/- 1.1) days (P = 0.011).

Documentos Relacionados

• Oral acyclovir therapy of genital herpes simplex virus type 2 infections in guinea pigs.
• Acyclovir therapy of neonatal herpes simplex virus type 2 infections in rabbits.
• Alteration of lymphocyte transformation response to herpes simplex virus infection by acyclovir therapy.
• Acyclovir vs isoprinosine (immunovir) for suppression of recurrent genital herpes simplex infection.
• Development of Clinical Resistance to Acyclovir in Herpes Simplex Virus-Infected Mice Receiving Oral Therapy